Firefly Bio Acquired by Johnson & Johnson | Healthcare M&A Deal

Johnson & Johnson has acquired Firefly Bio, a medical devices business in the healthcare sector in the United States. Firefly Bio acquisition centers on a novel degrader antibody conjugate platform intended to support oncology pipeline expansion and next-generation targeted therapies. Johnson & Johnson acquisitions also reflect broader healthcare M&A strategy to strengthen capabilities in cancer treatment modalities using antibody conjugates. The other acquisition is a strategic acquisition by a corporate buyer, with deal size undisclosed and status announced, as Johnson & Johnson acquisitions seek to accelerate translational development through platform technology.